| Price | $10.39 |
| Year Range | $8.36 – $14.75 |
| Market Cap | $672M |
| PE Ratio | 12.3 |
| Industry | Biotechnology |
What Is Zevra Therapeutics’s AI Stock Analysis?
Zevra Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Zevra Therapeutics’s momentum in near-real time.
Zevra Therapeutics (ZVRA) has an AltIndex AI Score of 50/100, currently a Hold signal. The AI Score distills Zevra Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Zevra Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Zevra Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ZVRA’s AI Score?
Fundamentals
Revenue for the last quarter was $40M. This is an increase of 9.51% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 53.25%, suggesting positive year-over-year growth. Net income for the last quarter was $8.8M. This represents a decrease of 76.90% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 88.28%, which may be a cause for concern. Ebitda for the last quarter was $13M. This represents a decrease of 69.84% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 83.73%, which may be a cause for concern. The current P/E ratio is 12.3. This appears to be within a normal range, neither particularly high nor low.
See Zevra Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $10.39. This represents a decrease of 13.49% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 0.95%, which could be a cause for long-term concern. The trend is bullish. The current SMA10 is $10.94, which is higher than the previous SMA10 of $10.90. This indicates a potential upward trend in price movement. The RSI is 58.2, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Zevra Therapeutics has an estimated 12 open positions. This number is up by 20% in the last couple of months, indicating a company that looking to grow and expand. Potentially a healthy sign. Zevra Therapeutics has an estimate of 13,000 visitors to their webpage. The number of visitors is up by 86% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Zevra Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Zevra Therapeutics has 790 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Zevra Therapeutics’s market sentiment.
Frequently Asked Questions: Zevra Therapeutics AI Stock Analysis
Zevra Therapeutics's AltIndex AI Score is 50/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Zevra Therapeutics a Hold (50/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Zevra Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ZVRA AI Score or sign up to read the full thesis.
